TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Explore linked clinical trials.2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | DNA Virus Infections, Infections, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, skin disorder, skin neoplasm, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2026-04-17 | NCT06947928 | |
| IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | DNA Virus Infections, Infections, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, viral infectious disease | Recruiting | Phase 1 | 2025-10-15 | NCT06940440 |